Borderline ovarian tumors don’t have a single identifiable cause, but researchers have pinpointed several genetic mutations, hormonal factors, and biological conditions that drive their development. These tumors sit between benign cysts and invasive ovarian cancer, growing abnormally but not invading surrounding tissue. They tend to affect younger women than invasive ovarian cancer, with a median age at diagnosis of about 49, and roughly 30% of cases occur in women under 40.
How These Tumors Develop at the Cellular Level
Borderline ovarian tumors follow a stepwise progression that begins in otherwise normal or benign ovarian tissue. The serous subtype, which is the most common, typically starts as a benign cyst (called a cystadenoma) or a fibrous growth on the ovary. Over time, cells in that growth acquire specific genetic mutations that push them toward abnormal proliferation without crossing the line into full invasion of surrounding tissue.
This is a key distinction from the aggressive, high-grade ovarian cancers that most people think of. High-grade serous ovarian cancer develops through an entirely different molecular pathway. Borderline tumors and high-grade cancers are not stages of the same disease. Instead, they represent two separate routes of tumor development that happen to originate in the same organ.
The mucinous subtype follows a similar stepwise pattern: a benign mucinous cyst acquires mutations, progresses to a borderline tumor, and in some cases can eventually develop into invasive mucinous carcinoma. Endometrioid borderline tumors often arise from endometriosis tissue on or near the ovary, progressing through benign growths before reaching the borderline stage.
Genetic Mutations That Drive Growth
Two specific gene mutations account for roughly two-thirds of serous borderline ovarian tumors. Mutations in the KRAS gene appear in 17% to 40% of cases, while BRAF gene mutations appear in 23% to 48%. Both genes control a signaling pathway that tells cells when to grow and divide. When either gene is mutated, cells receive a constant “grow” signal even when they shouldn’t.
These mutations show up very early in the process. Researchers have detected them in the benign cysts that sit alongside borderline tumors, which means the genetic change happens before the tumor looks abnormal under a microscope. It’s one of the earliest events that sets the entire progression in motion.
Mucinous borderline tumors carry KRAS mutations even more frequently, in over 60% of cases. In contrast, high-grade serous ovarian cancers almost never carry KRAS or BRAF mutations. They’re driven instead by mutations in the p53 gene, which is altered in more than half of aggressive serous cancers but rarely found in borderline tumors. This molecular fingerprint is what confirms borderline tumors and high-grade ovarian cancers are fundamentally different diseases.
The Role of Body Weight
Higher body weight is one of the more consistent risk factors for borderline ovarian tumors, particularly the serous subtype. Data from the Ovarian Cancer Association Consortium, one of the largest pooled analyses on the topic, found that each 5 kg/m² increase in BMI (roughly 30 pounds for an average-height woman) raised the risk of borderline serous tumors by about 24%.
The numbers become more striking at higher BMI levels. Compared to women with a BMI under 25, women with a BMI of 30 to 35 had an 86% higher risk of borderline serous tumors. Women with a BMI of 40 or above had more than double the risk. The association held regardless of menopausal status or hormone replacement therapy use.
Borderline mucinous tumors also showed a connection to body weight, though a weaker one. The risk increase was about 9% per 5 kg/m² of BMI, becoming statistically significant mainly at the highest weight categories. The biological explanation likely involves the hormonal environment that excess body fat creates: fat tissue produces estrogen, and higher circulating estrogen levels can stimulate ovarian cell growth.
Fertility Treatments and Ovarian Stimulation
Women who undergo fertility treatment with ovarian-stimulating drugs face a modestly elevated risk of borderline ovarian tumors. A large meta-analysis found that fertility drug use increased the risk of borderline tumors by about 32% compared to women who didn’t use these medications. The combination of clomiphene and gonadotropins (two commonly used fertility drugs) was specifically associated with higher borderline tumor risk.
The connection makes biological sense: these drugs force the ovaries to produce multiple eggs per cycle, dramatically increasing cell division in ovarian tissue. More cell division means more opportunities for the kind of genetic errors that initiate tumor growth. However, the picture is nuanced. When researchers broke the data down by number of treatment cycles or cumulative drug dose, none of the individual subgroups reached statistical significance for borderline tumors. This suggests the overall risk increase is real but modest, and that no specific dosing threshold clearly triggers tumor development.
It’s also difficult to separate the effect of the drugs from the effect of infertility itself, since women who need fertility treatment may already have underlying ovarian conditions that raise their baseline risk.
Endometriosis as a Precursor
Endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, has a notable relationship with certain borderline tumor subtypes. In a multicenter study of women diagnosed with endometrioid borderline ovarian tumors, 34% had a prior history of endometriosis. That’s a strikingly high overlap given that endometriosis affects roughly 10% of women of reproductive age.
The connection is most relevant for endometrioid and clear cell borderline tumors. Researchers have documented a progression pattern where endometriosis tissue on the ovary transforms into a benign endometrioid growth, then into a borderline tumor, and occasionally into invasive endometrioid carcinoma. Each stage has been found sitting adjacent to the next in surgical specimens, providing strong evidence of a direct developmental pathway. Serous borderline tumors, by contrast, don’t appear to be linked to endometriosis.
Who Is Most Often Affected
Borderline ovarian tumors are diagnosed across a wide age range, from teenagers to women in their 90s. But compared to invasive ovarian cancer, the age distribution skews younger. In a study of 950 patients, the median age was 49, and nearly 30% of patients were under 40. Invasive epithelial ovarian cancer, by comparison, is most commonly diagnosed in women in their 60s.
This age pattern aligns with what’s known about the biology. Because borderline tumors develop through a slow, stepwise accumulation of mutations in a low-grade pathway, they can reach a detectable size earlier in life than aggressive cancers that require a different, more catastrophic set of genetic changes. Younger women diagnosed with borderline tumors generally have favorable outcomes, and the absence of destructive tissue invasion is a defining characteristic that separates these tumors from true ovarian cancer at any age.